Literature DB >> 2783023

Flucloxacillin compared with cefazolin in short-term prophylaxis for clean orthopedic surgery.

J Van Meirhaeghe1, R Verdonk, G Verschraegen, P Myny, G Paeme, H Claessens.   

Abstract

Two-hundred and fifty-two patients were included in a prospective, randomized, double-blind trial comparing the efficacy of flucloxacillin with that of cefazolin for clean orthopedic surgery. The preventive antibiotic regimen consisted of three 1-g injections perioperatively. There were 126 patients in each group, and the follow-up period was at least 6 months. Two deep (1.6%) and five superficial (4.0%) infections occurred in the flucloxacillin group. Three deep (2.4%) and five superficial (4.0%) infections developed in the cefazolin group.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2783023     DOI： 10.1007/BF00932321

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN： 0936-8051            Impact factor:   3.067


  22 in total

1.  A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis.

Authors:  A P Wilson; T Treasure; M F Sturridge; R N Grüneberg
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

2.  [Postoperative infectious risk in traumatic bone surgery and protocol for antibiotic therapy].

Authors:  J Andreu; J Barsotti; P Laudat; A Audurier
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  1984

3.  A survey of prophylactic antibiotic use for total joint replacements in a community hospital.

Authors:  E P Armstrong; D L Kopp
Journal:  Drug Intell Clin Pharm       Date:  1985-10

4.  Prevention of postoperative infection.

Authors:  E J Lowbury
Journal:  Injury       Date:  1985-11       Impact factor: 2.586

5.  Prophylactic antibiotics in hip fractures. A double-blind, prospective study.

Authors:  J W Burnett; R B Gustilo; D N Williams; A C Kind
Journal:  J Bone Joint Surg Am       Date:  1980-04       Impact factor: 5.284

6.  Prophylactic cefamandole in orthopaedic surgery.

Authors:  J M Gatell; J Riba; M L Lozano; J Maña; R Ramon; J García SanMiguel
Journal:  J Bone Joint Surg Am       Date:  1984-10       Impact factor: 5.284

7.  Flucloxacillin in bone.

Authors:  P F Unsworth; F W Heatley; I Phillips
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

8.  Duration of antibiotic prophylaxis. An experimental study.

Authors:  K S Scher; A F Wroczynski; C W Jones
Journal:  Am J Surg       Date:  1986-02       Impact factor: 2.565

9.  Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.

Authors:  R Sutherland; E A Croydon; G N Rolinson
Journal:  Br Med J       Date:  1970-11-21

10.  The effect of the combined use of a clean air system and one day prophylactic administration of cefamandole in total hip replacement.

Authors:  J C Mulier; N Cheng; B Van Tornout; J Vandepitte; H Debruyne
Journal:  Arch Orthop Trauma Surg       Date:  1981
View more
  4 in total

Review 1.  Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures.

Authors:  William J Gillespie; Geert Him Walenkamp
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

2.  A comparative study of 5 different antibiotic prophylaxis regimes in 4500 total knee replacements.

Authors:  Satish Babu; Bilal Al-Obaidi; Alan Jardine; Sam Jonas; Nawfal Al-Hadithy; Venkat Satish
Journal:  J Clin Orthop Trauma       Date:  2018-12-14

3.  Prophylactic antibiotics in elective hip and knee arthroplasty: an analysis of organisms reported to cause infections and National survey of clinical practice.

Authors:  C J Hickson; D Metcalfe; S Elgohari; T Oswald; J P Masters; M Rymaszewska; M R Reed; A P Sprowson
Journal:  Bone Joint Res       Date:  2015-11       Impact factor: 5.853

Review 4.  Antibiotics and antiseptics for preventing infection in people receiving revision total hip and knee prostheses: a systematic review of randomized controlled trials.

Authors:  Jeffrey Voigt; Michael Mosier; Rabih Darouiche
Journal:  BMC Infect Dis       Date:  2016-12-12       Impact factor: 3.090
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.